Completed PHASE1 INTERVENTIONAL 4-arm NCT01614197

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Sponsor: Pfizer

Conditions Lymphoblastic Leukemia, Acute, Childhood Lymphoblastic Lymphoma Peripheral T-cell Lymphoma

Interventions Cyclophosphamide Cytarabine Etoposide Hydrocortisone Methotrexate Temsirolimus

Updated 12 times since 2017 Last updated: Jul 25, 2023 Started: Jul 3, 2015 Primary completion: Dec 15, 2019 Completion: Sep 4, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01614197, this PHASE1 trial focuses on Lymphoblastic Leukemia, Acute, Childhood and Lymphoblastic Lymphoma and remains completed. Sponsored by Pfizer, it has been updated 12 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Aug 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Aug 2023 [monthly]

Completed PHASE1

▶ Show 7 earlier versions

Aug 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Mar 2020 — Aug 2020 [monthly]

Recruiting PHASE1
Jun 2019 — Mar 2020 [monthly]

Recruiting PHASE1
Jul 2018 — Jun 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Therapeutic Advances in Childhood Leukemia Consortium

Data source: Therapeutic Advances in Childhood Leukemia Consortium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Boston, United States , Brisbane, Australia , Charlotte, United States , Chicago, United States , Cleveland, United States , Columbus, United States and 22 more locations